Adapted ECHO-7 virus RIGVIR® immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study
The results of a retrospective effectiveness study using the oncolytic virus Rigvir® published online by Melanoma Research, July 15, 2015
The study reveals that the stage IB-IIC melanoma patients treated with Rigvir® were 4 to 6 times more likely to survive than those who, following the current guidelines for the treatment of melanoma, received no therapy and were observed only. Moreover, Rigvir® demonstrated an outstanding safety profile because there was no record of any untoward side effect from Rigvir® treatment or its discontinuation. The results indicate that a significant number of melanoma patients would benefit from prolonging survival with Rigvir® treatment.
Source: Melanoma Research. 2015 Jul 24. Doniņa S, Strēle I, Proboka G, Auziņš J, Alberts P, Jonsson B, Venskus D, Muceniece A.
As known, RIGVIR® has been registered as an immunomodulator and for the treatment of melanoma, though researchers continue to develop research for other indications, through preclinical studies and clinical trial.
In addition, several doctors who have applied RIGVIR® for off-label use in their practice (based on international experience) have documented cases where RIGVIR® has successfully cured patients with other cancer diagnoses.
Few of these cases are published in medical journals which you can see below.
Such individual cases encourage Rigvir Group scientists to develop successful cases and plan clinical trials for the treatment of other cancer diagnosis, such as stomach cancer, colorectal cancer, pancreatic cancer, kidney cancer, uterine cancer, bladder cancer, lung cancer, prostate cancer and several types of sarcoma.